Asset profile
Everolimus
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Epilepsy, HR+/HER2- Metastatic Breast Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Featured evidence outside covered markets:EXIST-2 (NCT00790400) · Tuberous Sclerosis Complex (TSC), Lymphangioleiomyomatosis (LAM) · Phase 3 · met primary endpoint · Reliable signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
120 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 120 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Everolimus: this drug | Approved | Small molecule | mTOR (mTORC1) (inhibitor), mTOR kinase | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Brivaracetam | Approved | Small molecule | Synaptic vesicle glycoprotein 2A (SV2A) | ||
| Cannabidiol (Epidiolex) | Approved | Small molecule | GPR55 / TRPV1 / adenosine transport (multi-target), cannabinoid | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Carbamazepine | Approved | Small molecule | Sodium channels | ||
| Cenobamate (Xcopri) | Approved | Small molecule | Sodium channels + GABA-A receptors | ||
| Clobazam (Onfi) | Approved | Small molecule | GABA-A receptor | ||
| Clobazam (Sympazan) | Approved | Small molecule | GABA-A receptor (benzodiazepine site) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Diastat | Approved | Combination | GABA-A receptor | ||
| Diazepam (Valium) | Approved | Small molecule | GABA-A receptor |
…and 105 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(63 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (9)
October 2026 (1)
Phase 4Renal AngiomyolipomaActive not recruiting
Est. primary completion 2026-10-10 · NCT05252585 · CT.gov ↗
What to watch
November 2026 (1)
Phase 1/2Unresectable Locally Advanced or Metastatic Solid TumorsNot yet recruiting
Est. primary completion 2026-11-13 · NCT06682611 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1Acute Myeloid Leukemia, Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2026-12 · NCT00819546 · CT.gov ↗
What to watch
Phase 2Soft Tissue SarcomaActive not recruiting
Est. primary completion 2026-12 · NCT03114527 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-12-27 · NCT05563220 · CT.gov ↗
What to watch
Phase 1ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement …Active not recruiting
Est. primary completion 2026-12-31 · NCT02321501 · CT.gov ↗
What to watch
Phase 1/2Colorectal CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT07435584 · CT.gov ↗
What to watch
2027 (19)
January 2027 (1)
Phase 3Coronary Artery DiseaseActive not recruiting
Est. primary completion 2027-01-13 · NCT05952206 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1/2ProgeriaEnrolling by invitation
Est. primary completion 2027-03 · NCT02579044 · CT.gov ↗
What to watch
Phase 4Carcinoma, HepatocellularEnrolling by invitation
Est. primary completion 2027-03 · NCT02081755 · CT.gov ↗
What to watch
Phase 2Healthy, Osteopenia, Osteoporosis RiskRecruiting
Est. primary completion 2027-03-01 · NCT07191353 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Thyroid CancerActive not recruiting
Est. primary completion 2027-06 · NCT01141309 · CT.gov ↗
What to watch
July 2027 (2)
August 2027 (2)
Phase 3Tuberous Sclerosis ComplexActive not recruiting
Est. primary completion 2027-08-04 · NCT02962414 · CT.gov ↗
What to watch
Early phase / not applicableCoronary Artery Disease, Coronary Artery Stenosis, Percutaneous Coronary Intervention, de Novo Lesions in Native Coronary ArteriesNot yet recruiting
Est. primary completion 2027-08-17 · NCT07098195 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (1)
Phase 2Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-10-25 · NCT05012371 · CT.gov ↗
What to watch
December 2027 (6)
Early phase / not applicableKidney Transplant Failure and RejectionRecruiting
Est. primary completion 2027-12-03 · NCT03955172 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma Stage IRecruiting
Est. primary completion 2027-12-27 · NCT06730672 · CT.gov ↗
What to watch
Phase 1Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High-Grade Glioma (HGG)Recruiting
Est. primary completion 2027-12-31 · NCT04485559 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT05508906 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05749588 · CT.gov ↗
What to watch
Early phase / not applicableKidney Transplant Infection, BK Virus InfectionActive not recruiting
Est. primary completion 2027-12-31 · NCT04542733 · CT.gov ↗
What to watch
2028 (17)
January 2028 (3)
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 4CMV InfectionNot yet recruiting
Est. primary completion 2028-01 · NCT07570433 · CT.gov ↗
What to watch
Phase 2Kidney CancerActive not recruiting
Est. primary completion 2028-01-31 · NCT01217931 · CT.gov ↗
What to watch
February 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-02 · NCT05573126 · CT.gov ↗
What to watch
March 2028 (1)
Phase 2Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm …Active not recruiting
Est. primary completion 2028-03-30 · NCT03950609 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-05-01 · NCT07002177 · CT.gov ↗
What to watch
June 2028 (1)
Phase 2Liver TransplantRecruiting
Est. primary completion 2028-06-30 · NCT06280950 · CT.gov ↗
What to watch
July 2028 (2)
August 2028 (3)
Phase 1Phase IB, Avutometinib, RAS Pathway, EndometrialRecruiting
Est. primary completion 2028-08-01 · NCT07318324 · CT.gov ↗
What to watch
Phase 2Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Carcinoma …Active not recruiting
Est. primary completion 2028-08-31 · NCT03008408 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-08-31 · NCT06680921 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Atypical Endometrial Hyperplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid AdenocarcinomaActive not recruiting
Est. primary completion 2028-09-30 · NCT02397083 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Neoplasms of Bone and Articular Cartilage With Unspecified Anatomical SiteNot yet recruiting
Est. primary completion 2028-11-30 · NCT07619950 · CT.gov ↗
What to watch
December 2028 (3)
Phase 2Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer …Not yet recruiting
Est. primary completion 2028-12-18 · NCT07634601 · CT.gov ↗
What to watch
Phase 3Renal Cell Carcinoma (RCC)Not yet recruiting
Est. primary completion 2028-12-30 · NCT07165418 · CT.gov ↗
What to watch
Early phase / not applicableMetastatic Sarcoma, Recurrent Sarcoma, Resectable SarcomaRecruiting
Est. primary completion 2028-12-31 · NCT04199026 · CT.gov ↗
What to watch
2029 (7)
January 2029 (1)
Phase 2Solid Tumor, Adult, Hepatocellular CarcinomaRecruiting
Est. primary completion 2029-01-01 · NCT04803318 · CT.gov ↗
What to watch
April 2029 (1)
Phase 1Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-04-16 · NCT06994572 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-05-30 · NCT04802759 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Liver Allograft, Liver Diseases, Liver TransplantationNot yet recruiting
Est. primary completion 2029-06-30 · NCT07739914 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma …Recruiting
Est. primary completion 2029-08-31 · NCT05843253 · CT.gov ↗
What to watch
October 2029 (1)
Early phase / not applicableCoronary Artery DiseaseRecruiting
Est. primary completion 2029-10-15 · NCT07190690 · CT.gov ↗
What to watch
November 2029 (1)
Phase 4Acute Coronary SyndromeRecruiting
Est. primary completion 2029-11 · NCT06718179 · CT.gov ↗
What to watch
2030 (7)
June 2030 (1)
Phase 1Liver TransplantRecruiting
Est. primary completion 2030-06-01 · NCT06832189 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Carcinom, HepatocellularNot yet recruiting
Est. primary completion 2030-07-01 · NCT06972758 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome …Not yet recruiting
Est. primary completion 2030-09 · NCT07218575 · CT.gov ↗
What to watch
October 2030 (2)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-10 · NCT05933395 · CT.gov ↗
What to watch
Phase 2Vascular Malformations, Arteriovenous Malformations, Venous Malformation, Lymphangioma, Nevus, Port-Wine, Hemangioendothelioma, HemangiomaNot yet recruiting
Est. primary completion 2030-10-31 · NCT07477548 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
June 2031 (1)
Phase 2Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-positive Breast Cancer …Recruiting
Est. primary completion 2031-06-02 · NCT07340541 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 3Breast Cancer Females, Triple Negative Breast Cancer (TNBC)Not yet recruiting
Est. primary completion 2033-02-01 · NCT07407517 · CT.gov ↗
What to watch
2038 (1)
December 2038 (1)
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2038-12-31 · NCT05725200 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.